TELA Bio CEO Antony Koblish departs; Heather Getz appointed CEO and director

TELA Bio, Inc.

Antony Koblish ceased as CEO and resigned from board on Aug 3, 2026; no disagreement with company.
Heather Getz appointed CEO and Class II director effective Aug 3, 2026; 25+ years healthcare experience.
Employment agreement: $650k base salary, 100% target bonus, severance, and initial equity grants.
Initial equity grants: 1,365,000 standard options, 1,005,000 premium-priced options, 500,000 RSUs.
Potential top-up grants if equity financings within 18 months; total could reach 5% of outstanding shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.